WATCHMAN FLXTM
Left Atrial Appendage Closure Device
Setting the Standard
Built on the most studied and implanted LAAC device in the world with 200,000+ patients treated and 20 years of clinical and real-world experience – including 10+ clinical trials – WATCHMAN FLX sets the standard for LAAC.
WATCHMAN FLX Data
The SURPASS analysis of the NCDR-LAAC Registry™ reinforces the outstanding safety of WATCHMAN FLX with 0.37% major procedural adverse event rate within 7 days or hospital discharge and 98% procedural success rate in >16,000 real world NVAF patients.1
WATCHMAN LAAC Integrated Solutions
WATCHMAN™ TruPlan™ CT Imaging Software is purpose-built to facilitate patient screening and procedure planning for LAAC. WATCHMAN TruPlan Software offers a full feature set that allows you to visualize each unique anatomy and to create a customized procedure plan for your LAAC implants.
WATCHMAN FXD Curve™ Access System
The WATCHMAN FXD Curve™ Access System is designed for the WATCHMAN FLX™ LAAC device, bringing smoother deployment and successful placement to the delivery of the most studied and implanted LAAC device in the world.
WATCHMAN FLX DAPT Approval
FDA approves use of DAPT or OAC immediately following implant with WATCHMAN FLX device.
Learn More About WATCHMAN FLX
Access Resources
Access WATCHMAN FLX device resources by visiting our WATCHMAN Download Center
Rep Visit
Connect with a local representative to learn more about the WATCHMAN FLX device
WATCHMAN™ TruPlan™ is developed and owned by Circle Cardiovascular Imaging Inc. (Calgary, AB, Canada), and Boston Scientific is the exclusive reseller of WATCHMAN TruPlan.
Sources:
- Late Breaking Clinical Trial at CRT 2022, Presented by Dr. Samir Kapadia